CA2732436C - Vaccine against hpv - Google Patents

Vaccine against hpv Download PDF

Info

Publication number
CA2732436C
CA2732436C CA2732436A CA2732436A CA2732436C CA 2732436 C CA2732436 C CA 2732436C CA 2732436 A CA2732436 A CA 2732436A CA 2732436 A CA2732436 A CA 2732436A CA 2732436 C CA2732436 C CA 2732436C
Authority
CA
Canada
Prior art keywords
hpv
dose
vaccine
gmt
vlps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2732436A
Other languages
English (en)
French (fr)
Other versions
CA2732436A1 (en
Inventor
Dominique Descamps
Sandra Giannini
Nicolas Lecrenier
Jean Stephenne
Martine Anne Cecile Wettendorff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA2732436A1 publication Critical patent/CA2732436A1/en
Application granted granted Critical
Publication of CA2732436C publication Critical patent/CA2732436C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2732436A 2008-07-31 2009-07-29 Vaccine against hpv Active CA2732436C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8510108P 2008-07-31 2008-07-31
US61/085,101 2008-07-31
US17656109P 2009-05-08 2009-05-08
US61/176,561 2009-05-08
PCT/EP2009/059820 WO2010012780A1 (en) 2008-07-31 2009-07-29 Vaccine against hpv

Publications (2)

Publication Number Publication Date
CA2732436A1 CA2732436A1 (en) 2010-02-04
CA2732436C true CA2732436C (en) 2018-01-16

Family

ID=41139260

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2732436A Active CA2732436C (en) 2008-07-31 2009-07-29 Vaccine against hpv

Country Status (26)

Country Link
US (1) US20110189229A1 (enExample)
EP (1) EP2318042B1 (enExample)
JP (1) JP6022159B2 (enExample)
KR (1) KR20110053340A (enExample)
CN (1) CN102159239A (enExample)
AU (1) AU2009275909A1 (enExample)
BR (1) BRPI0916732B1 (enExample)
CA (1) CA2732436C (enExample)
CO (1) CO6341567A2 (enExample)
DK (1) DK2318042T3 (enExample)
DO (1) DOP2011000031A (enExample)
EA (1) EA201170264A1 (enExample)
ES (1) ES2519490T3 (enExample)
HR (1) HRP20141063T1 (enExample)
IL (1) IL210977A0 (enExample)
MA (1) MA32554B1 (enExample)
MX (1) MX2011001218A (enExample)
NZ (1) NZ590919A (enExample)
PE (1) PE20110327A1 (enExample)
PL (1) PL2318042T3 (enExample)
PT (1) PT2318042E (enExample)
RS (1) RS53607B1 (enExample)
SI (1) SI2318042T1 (enExample)
SM (1) SMT201400170B (enExample)
WO (1) WO2010012780A1 (enExample)
ZA (1) ZA201100889B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2768172A1 (en) 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
CN102178944A (zh) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
RU2628693C1 (ru) * 2016-11-10 2017-08-21 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ
US20210302427A1 (en) * 2020-03-31 2021-09-30 Shuhari Group, LLC Secure Immunity Information Transmission System And Network
KR20260109890A (ko) * 2024-01-04 2026-07-13 사이안백 엘엘씨 백신 조성물에 증가된 안정성을 제공하는 개선된 제형

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP1732598A4 (en) * 2003-12-31 2009-08-26 Pharmexa Inc TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
KR20070029254A (ko) * 2004-06-16 2007-03-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신
AR054259A1 (es) * 2005-04-26 2007-06-13 Glaxosmithkline Biolog Sa Vacuna contra virus de papiloma humano (hpv)

Also Published As

Publication number Publication date
SMT201400170B (it) 2015-01-15
DK2318042T3 (da) 2014-11-10
BRPI0916732B1 (pt) 2021-06-29
CO6341567A2 (es) 2011-11-21
DOP2011000031A (es) 2011-02-28
NZ590919A (en) 2012-10-26
WO2010012780A1 (en) 2010-02-04
EP2318042B1 (en) 2014-08-20
MA32554B1 (fr) 2011-08-01
KR20110053340A (ko) 2011-05-20
US20110189229A1 (en) 2011-08-04
CN102159239A (zh) 2011-08-17
PL2318042T3 (pl) 2015-02-27
MX2011001218A (es) 2011-03-15
AU2009275909A1 (en) 2010-02-04
JP6022159B2 (ja) 2016-11-09
BRPI0916732A2 (pt) 2017-01-31
RS53607B1 (sr) 2015-04-30
SI2318042T1 (sl) 2014-12-31
CA2732436A1 (en) 2010-02-04
EP2318042A1 (en) 2011-05-11
PT2318042E (pt) 2014-11-05
JP2011529475A (ja) 2011-12-08
PE20110327A1 (es) 2011-06-29
IL210977A0 (en) 2011-04-28
HRP20141063T1 (hr) 2015-01-02
ES2519490T3 (es) 2014-11-07
ZA201100889B (en) 2012-04-25
EA201170264A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
EP2318042B1 (en) Vaccine against hpv
CN100528226C (zh) 人乳头瘤病毒的病毒样颗粒
MX2011013744A (es) Construcciones novedosas de proteinas del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv.
JP2012102132A (ja) Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
US20150110824A1 (en) Method of vaccination against human papillomavirus
CA2566620C (en) Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52
US7758866B2 (en) Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CN101217975A (zh) 疫苗
AU2006239471A1 (en) Vaccine
HK1128872A (en) Viral antigens

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140430

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627